fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

CHMP positive for Nemluvio (nemolizumab) for the treatment of both atopic dermatitis and prurigo nodularis – Galderma

Written by | 27 Jan 2025

Galderma  announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing… read more.

FDA approves for Nemluvio (nemolizumab) for adult patients living with prurigo nodularis – Galderma

Written by | 23 Aug 2024

Galderma announced that the FDA has approved Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemluvio was granted Breakthrough… read more.

FDA approves Twyneo to treat acne vulgaris – Galderma + Sol-Gen Technologies

Written by | 20 Aug 2021

Sol-Gel Technologies, Ltd. announced that the FDA has approved its first proprietary drug product, Twyneo (tretinoin/benzoyl peroxide) cream, 0.1%/3%, indicated for the treatment of acne vulgaris in adults… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.